Belite Bio CSO reports option and share holdings

Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings.

Rhea-AI Filing Summary

Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider MATA NATHAN L.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	American depositary share	--	--	--
holding	Ordinary Share	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 323,066 contracts (Direct); American depositary share — 16,666 shares (Direct); Ordinary Share — 16,666 shares (Direct)

Footnotes (4)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.
2. F2. The option to purchase 123,066 ordinary shares had vested prior to March 18, 2026.
3. F3. The option shall vest (i) as to 50,000 ordinary shares on July 17, 2023, and (ii) as to 50,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following July 17, 2023, subject to continued service to the Issuer on each such date.
4. F4. The option shall vest as to 100,000 ordinary shares in 36 equal and continue monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Belite Bio (BLTE) disclose in Nathan L. Mata’s Form 3?

The Form 3 discloses Chief Scientific Officer Nathan L. Mata’s existing equity holdings in Belite Bio. It lists his stock options on ordinary shares, their exercise prices and expirations, plus his direct holdings of American depositary shares and ordinary shares.

How many stock options does Belite Bio’s CSO hold according to this filing?

The CSO holds options linked to 123,066 ordinary shares at $6.0000, 100,000 shares at $14.4500, and 100,000 shares at $48.4600. Each grant has its own expiration date and service-based vesting schedule described in the filing footnotes.

What are the exercise prices and expirations of Belite Bio (BLTE) options in this Form 3?

The filing lists options with exercise prices of $6.0000 expiring April 17, 2032, $14.4500 expiring July 16, 2033, and $48.4600 expiring August 28, 2034. These options relate to ordinary shares of Belite Bio, Inc.

How much of Nathan L. Mata’s Belite Bio option grant was already vested?

The filing states that the option to purchase 123,066 ordinary shares had vested before March 18, 2026. Other option grants vest over time in equal monthly installments, conditioned on his continued service with Belite Bio, Inc. on each vesting date.

What shareholdings besides options are reported for Belite Bio’s CSO?

The report shows direct holdings of 16,666 American depositary shares and 16,666 ordinary shares. A footnote explains that each ADS represents one ordinary share of Belite Bio, giving investors clarity on how these two line items relate economically.

Are there any buy or sell transactions in Belite Bio (BLTE) CSO’s Form 3?

The Form 3 functions as an initial ownership report and only lists existing holdings. It shows stock option positions and direct share holdings, without recording any purchases, sales, gifts, or tax-withholding transactions on the reported date for Belite Bio’s Chief Scientific Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 02:45 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last) (First) (Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American depositary share(1)	16,666	D
Ordinary Share	16,666	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	04/17/2032	Ordinary Shares	123,066	$6	D
Stock Option (right to buy)	(3)	07/16/2033	Ordinary Shares	100,000	$14.45	D
Stock Option (right to buy)	(4)	08/28/2034	Ordinary Shares	100,000	$48.46	D

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.

2. The option to purchase 123,066 ordinary shares had vested prior to March 18, 2026.

3. The option shall vest (i) as to 50,000 ordinary shares on July 17, 2023, and (ii) as to 50,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following July 17, 2023, subject to continued service to the Issuer on each such date.

4. The option shall vest as to 100,000 ordinary shares in 36 equal and continue monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ NATHAN L. MATA	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)